Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 226 - 250 of 895 in total
A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Approved
Matched Categories: … Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) …
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) …
Cephalexin is the first of the first generation cephalosporins.[A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,Label] Cephalexin was approved by the FDA on 4 January 1971.
Approved
Investigational
Vet approved
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by...
Approved
Illicit
Matched Categories: … Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712,...
Approved
Illicit
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) …
A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
Approved
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Fluocinolone acetonide, with the formula 6-alpha, 9-alpha-difluoro-16-alpha, 17 alpha-acetonide, is a corticosteroid that presents a high lipophilicity. It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices. This type of device containing fluocinolone acetonide was developed by Taro...
Approved
Investigational
Vet approved
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Rizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Used in the treatment of migraines, rizatriptan was first approved in the US in 1998. Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.
Approved
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and...
Approved
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning...
Approved
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Approved
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Salbutamol (Albuterol [USAN]) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a...
Approved
Vet approved
Matched Categories: … Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).[L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause...
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) …
Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 )...
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal...
Approved
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2A6 Inducers (strength unknown) …
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.[L7456,L7459] It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel.[A259676,L46466] Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed,...
Approved
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) …
Displaying drugs 226 - 250 of 895 in total